Aticaprant
Sponsors
Janssen Research & Development, LLC
Conditions
AnhedoniaDepressive Disorder, MajorSchizophrenia
Phase 1
Phase 3
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
CompletedNCT05455684
Start: 2022-06-22End: 2024-09-18Updated: 2025-11-06
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
TerminatedNCT05518149
Start: 2022-09-22End: 2025-05-08Updated: 2026-04-15
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
CompletedNCT05550532
Start: 2022-12-06End: 2024-11-13Updated: 2026-02-13
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
TerminatedNCT06514742
Start: 2024-06-26End: 2025-04-24Updated: 2026-02-17
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
TerminatedNCT06635135
Start: 2024-09-19End: 2025-04-25Updated: 2026-06-08